DrugPatentWatch Database Preview
Melinta Therap Company Profile
What is the competitive landscape for MELINTA THERAP, and when can generic versions of MELINTA THERAP drugs launch?
MELINTA THERAP has one approved drug.
There are four US patents protecting MELINTA THERAP drugs.
There are ninety-five patent family members on MELINTA THERAP drugs in thirty-three countries and eight supplementary protection certificates in eight countries.
Summary for Melinta Therap
| International Patents: | 95 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Melinta Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | 9,682,061 | Start Trial | Start Trial | ||||
| Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | 5,840,684 | Start Trial | Y | Y | Start Trial | ||
| Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | 8,420,592 | Start Trial | Start Trial | ||||
| Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | 9,649,352 | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Melinta Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | 5,998,581 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Melinta Therap Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Portugal | 817797 | Start Trial |
| European Patent Office | 1031576 | Start Trial |
| European Patent Office | 2424559 | Start Trial |
| China | 106620649 | Start Trial |
| Finland | 20050513 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Melinta Therap Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2337575 | 2016/040 | Ireland | Start Trial | PRODUCT NAME: ORITAVANCIN AND PHARMACEUTICAL SALTS THEREOF, E.G DIPHOSPHATE SALTS; REGISTRATION NO/DATE: EU/1/15/989 20150319 |
| 2337575 | 2016019 | Norway | Start Trial | PRODUCT NAME: ORITAVANCIN OG FARMASOEYTISK; REG. NO/DATE: EU/1/15/989 20150415 |
| 2337575 | CA 2016 00044 | Denmark | Start Trial | PRODUCT NAME: ORITAVANCIN OG/ELLER FARMACEUTISKE SALTE HERAF, HERUNDER DIFOSFATSALTE; REG. NO/DATE: EU/1/15/989 20150323 |
| 2337575 | 41/2016 | Austria | Start Trial | PRODUCT NAME: ORITAVANCIN UND DESSEN PHARMAZEUTISCHE SALZE; REGISTRATION NO/DATE: EU/1/15/989 (MITTEILUNG) 20150323 |
| 2337575 | 122016000075 | Germany | Start Trial | PRODUCT NAME: ORITAVANCIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/989 20150319 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
